Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.
about
Targeting the apoptosis pathway in hematologic malignanciesHow many diseases are colorectal cancer?Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Death receptors as targets in cancerRegulation of TRAIL-receptor expression by the ubiquitin-proteasome system.Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential.Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.The expression of selected proapoptotic molecules in dermatitis herpetiformis.TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.Dulanermin in cancer therapy: still much to do.Death Receptors: New Opportunities in Cancer Therapy.The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement.Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.Developing TRAIL/TRAIL death receptor-based cancer therapies.
P2860
Q27024422-4AE83C85-A164-4629-931A-F8CCA4A3A108Q36238965-989F22CE-8673-4F69-8FB0-274B8F7110DBQ36586167-070511F1-9052-476E-A656-45BC4564D4D9Q37602717-E9890CA3-3B1C-4B47-9E4C-EB93CD2FD6A1Q38103591-B0965548-3008-4CEB-9C73-FE235716B0A9Q38260461-D6F3D619-9CDB-4C9B-B238-41F6B9CED3C5Q38737133-0895E545-B64E-4B26-928E-3419C1B41643Q38885494-DAA61EF3-A307-4915-BA44-EE668256405AQ39126075-5A7A2423-2E12-4C3D-946E-5359345B2BE9Q41972240-A2D988C6-6C6C-4436-A52C-DA9BCEAC5DBDQ42623198-EEF43156-91CF-414F-A31B-4C298FBCF2C1Q43195748-C19BEFD4-2579-40CE-886C-3E16C13566DCQ47108799-42B40CE3-CF6A-48F7-A14B-8267AABF4A1AQ47832405-67B9BBD7-E1BF-405A-A8AB-A4983563A3DAQ51206705-A1970C15-1BB5-4FAD-98DC-EC3CFBF56275Q53701901-D3D5FB7D-33E3-464D-A542-F31037BE8154
P2860
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluation of pharmacodynamic ...... atients with advanced tumours.
@ast
Evaluation of pharmacodynamic ...... atients with advanced tumours.
@en
type
label
Evaluation of pharmacodynamic ...... atients with advanced tumours.
@ast
Evaluation of pharmacodynamic ...... atients with advanced tumours.
@en
prefLabel
Evaluation of pharmacodynamic ...... atients with advanced tumours.
@ast
Evaluation of pharmacodynamic ...... atients with advanced tumours.
@en
P2093
P2860
P356
P1476
Evaluation of pharmacodynamic ...... atients with advanced tumours.
@en
P2093
D Branstetter
P M Holland
R S Herbst
S G Eckhardt
P2860
P2888
P304
P356
10.1038/BJC.2011.456
P407
P577
2011-10-27T00:00:00Z